M. Fraenkel, M. Kim, A. Faggiano, and G. Valk, Epidemiology of gastroenteropancreatic neuroendocrine tumours, Best Practice & Research Clinical Gastroenterology, vol.26, issue.6, pp.691-703, 2012.
DOI : 10.1016/j.bpg.2013.01.006

C. Lepage, A. Bouvier, J. Phelip, C. Hatem, C. Vernet et al., Incidence and management of malignant digestive endocrine tumours in a well defined French population, Gut, vol.53, issue.4, pp.549-553, 2004.
DOI : 10.1136/gut.2003.026401

I. Modlin, K. Lye, and M. Kidd, A 50-Year Analysis of 562 Gastric Carcinoids: Small Tumor or Larger Problem?, The American Journal of Gastroenterology, vol.72, issue.1, pp.23-32, 2004.
DOI : 10.1073/pnas.192574799

C. Landry, G. Brock, C. Scoggins, K. Mcmasters, and R. Martin, A Proposed Staging System for Gastric Carcinoid Tumors Based on an Analysis of 1,543 Patients, Annals of Surgical Oncology, vol.12, issue.232, pp.51-60, 2009.
DOI : 10.3748/wjg.v12.i26.4267

M. B. Niederle, M. Hackl, K. Kaserer, and B. Niederle, Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters, Endocrine Related Cancer, vol.17, issue.4, pp.909-927, 2010.
DOI : 10.1677/ERC-10-0152

L. Vannella, A. Sbrozzi-vanni, and E. Lahner, Development of type I gastric carcinoid in patients with chronic atrophic gastritis, Alimentary Pharmacology & Therapeutics, vol.90, issue.Suppl. 1, pp.1361-1370, 2011.
DOI : 10.1159/000225952
URL : https://hal.archives-ouvertes.fr/hal-00632733

F. Gibril, M. Schumann, and A. Pace, Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome, Medicine, vol.83, issue.1, pp.43-83, 2004.
DOI : 10.1097/01.md.0000112297.72510.32

K. Borch, B. Ahren, and H. Ahlman, Gastric Carcinoids, Annals of Surgery, vol.242, issue.1, pp.64-73, 2005.
DOI : 10.1097/01.sla.0000167862.52309.7d

G. Rindi, C. Azzoni, L. Rosa, and S. , ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: Prognostic evaluation by pathological analysis, Gastroenterology, vol.116, issue.3, pp.532-542, 1999.
DOI : 10.1016/S0016-5085(99)70174-5

H. Scherübl, G. Cadiot, R. T. Jensen, T. Rösch, U. Stölzel et al., Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems?, Endoscopy, vol.42, issue.08, pp.664-671, 2010.
DOI : 10.1055/s-0030-1255564

S. Rappel, A. Altendorf-hofmann, and M. Stolte, Prognosis of Gastric Carcinoid Tumours, Digestion, vol.56, issue.6, pp.455-462, 1995.
DOI : 10.1159/000201276

Y. Sato, H. Imamura, and Y. Kaizaki, Management and clinical outcomes of type I gastric carcinoid patients: Retrospective, multicenter study in Japan, Digestive Endoscopy, vol.93, issue.3, pp.377-84, 2014.
DOI : 10.1002/jso.20468

D. Thomas, A. Tsolakis, S. Grozinsky-glasberg, M. Fraenkel, K. Alexandraki et al., Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study, European Journal of Endocrinology, vol.168, issue.2, pp.185-193, 2013.
DOI : 10.1530/EJE-12-0836

E. Merola, A. Sbrozzi-vanni, and F. Panzuto, Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate, Neuroendocrinology, vol.95, issue.3, pp.207-220, 2012.
DOI : 10.1159/000329043
URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.683.99

W. Chen, R. Warner, and S. Ward, Management and Disease Outcome of Type I Gastric Neuroendocrine Tumors: The Mount Sinai Experience, Digestive Diseases and Sciences, vol.12, issue.4, pp.996-1003, 2015.
DOI : 10.1016/S0960-7404(03)00034-3

Y. Sato, S. Hashimoto, K. Mizuno, M. Takeuchi, and S. Terai, Management of gastric and duodenal neuroendocrine tumors, World Journal of Gastroenterology, vol.22, issue.30, pp.6817-6845, 2016.
DOI : 10.1002/(SICI)1097-0142(19990315)85:6<1241::AID-CNCR5>3.0.CO;2-4
URL : http://doi.org/10.3748/wjg.v22.i30.6817

G. Delle-fave, D. Kwekkeboom, V. Cutsem, G. Rindi, B. Kos-kudla et al., ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms, Neuroendocrinology, vol.95, issue.2, pp.74-87, 2012.
DOI : 10.1159/000335595

E. Solcia, G. Kloppel, and L. Sobin, Histological typing of endocrine tumours In international histological classification of tumours, pp.61-68, 2000.

L. Sobin, M. Gospodarowicz, and W. Ch, UICC (International Union Against Cancer) TNM classification of malignant tumours, 2009.

C. Lepage, B. Rachet, and M. Coleman, Survival From Malignant Digestive Endocrine Tumors in England and Wales: A Population-Based Study, Gastroenterology, vol.132, issue.3, pp.899-904, 2007.
DOI : 10.1053/j.gastro.2007.01.006

C. Lepage, . Ciccolallo, . De-angelis, J. Bouvier, and . Faivre, Gatta and The EUROCARE working group. European disparities in malignant digestive endocrine tumours survival, Int J Cancer, vol.126, pp.2928-2934, 2010.

M. Kulke, L. Anthony, D. Bushnell, W. De-herder, S. Goldsmith et al., NANETS Treatment Guidelines, Pancreas, vol.39, issue.6, pp.735-52, 2010.
DOI : 10.1097/MPA.0b013e3181ebb168
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100728

R. Gladdy, V. Strong, D. Coit, P. Allen, H. Gerdes et al., Defining Surgical Indications for Type I Gastric Carcinoid Tumor, Annals of Surgical Oncology, vol.71, issue.3, pp.3154-60, 2009.
DOI : 10.1016/0016-5085(92)90787-Y

D. Ravizza, G. Fiori, C. Trovato, N. Fazio, G. Bonomo et al., Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours, Digestive and Liver Disease, vol.39, issue.6, pp.537-580, 2007.
DOI : 10.1016/j.dld.2007.01.018

S. Manfredi, M. Pagenault, A. De-lajarte-thirouard, and J. Bretagne, Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue, European Journal of Gastroenterology & Hepatology, vol.19, issue.11, pp.1021-1026, 2007.
DOI : 10.1097/MEG.0b013e328220eae0

S. Grozinsky-glasberg, G. Kaltsas, C. Gur, E. Gal, D. Thomas et al., Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours, European Journal of Endocrinology, vol.159, issue.4, pp.475-482, 2008.
DOI : 10.1530/EJE-08-0420
URL : http://www.eje-online.org/content/159/4/475.full.pdf

D. Campana, F. Nori, R. Pezzilli, L. Piscitelli, D. Santini et al., Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs, Endocrine Related Cancer, vol.15, issue.1, pp.337-342, 2008.
DOI : 10.1677/ERC-07-0251

M. Khuroo, M. Khuroo, and N. Khuroo, Treatment of type I gastric neuroendocrine tumors with somatostatin analogs, Journal of Gastroenterology and Hepatology, vol.34, issue.3, pp.548-54, 2010.
DOI : 10.1136/gut.34.1.28

P. Tomassetti, M. Migliori, G. Caletti, P. Fusaroli, R. Corinaldesi et al., Treatment of Type II Gastric Carcinoid Tumors with Somatostatin Analogues, New England Journal of Medicine, vol.343, issue.8, pp.551-555, 2000.
DOI : 10.1056/NEJM200008243430805

D. Campana, D. Ravizza, P. Ferolla, A. Faggiano, F. Grimaldi et al., Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study, Endocrine, vol.42, issue.3, pp.131-140, 2016.
DOI : 10.1016/j.humpath.2011.01.018

S. Massironi, V. Sciola, P. Spampatti, M. Peracchi, M. Conte et al., Gastric carcinoids: Between underestimation and overtreatment, World Journal of Gastroenterology, vol.15, issue.18, pp.2177-2183, 2009.
DOI : 10.3748/wjg.15.2177
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682231

. Promid-study and . Group, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group, J Clin Oncol, vol.27, pp.4656-63, 2009.

M. Caplin, M. Pavel, J. ?wik?a, A. Phan, M. Raderer et al., Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.371, issue.3, pp.224-257, 2014.
DOI : 10.1056/NEJMoa1316158

O. Toole, D. , D. Fave, G. Tensen, and R. , Gastric and duodenal neuroendocrine tumours, Best Practice & Research Clinical Gastroenterology, vol.26, issue.6, pp.719-754, 2012.
DOI : 10.1016/j.bpg.2013.01.002